Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.5.1.18 (
glutathione S-transferase
)
22,582
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Protein hydroxylation affects protein stability, activity, and interactome, therefore contributing to various diseases including cancers. However, the transiency of the hydroxylation reaction hinders the identification of hydroxylase substrates. By developing an enzyme-substrate trapping strategy coupled with TAP-TAG or orthogonal
GST
- purification followed by mass spectrometry, we identify
adenylosuccinate lyase
(
ADSL
) as an EglN2 hydroxylase substrate in triple negative breast cancer (TNBC).
ADSL
expression is higher in TNBC than other breast cancer subtypes or normal breast tissues.
ADSL
knockout impairs TNBC cell proliferation and invasiveness in vitro and in vivo. An integrated transcriptomics and metabolomics analysis reveals that
ADSL
activates the oncogenic cMYC pathway by regulating cMYC protein level via a mechanism requiring
ADSL
proline 24 hydroxylation. Hydroxylation-proficient
ADSL
, by affecting adenosine levels, represses the expression of the long non-coding RNA MIR22HG, thus upregulating cMYC protein level. Our findings highlight the role of
ADSL
hydroxylation in controlling cMYC and TNBC tumorigenesis.
...
PMID:Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer. 3172 79